By: Marijke Vroomen Durning, RN
Although researchers have been exploring gene editing for more than 40 years, scientists say the CRISPR technology offers game-changing methods for anticancer research as well as a host of other applications.
By: Jane de Lartigue, PhD
Genome sequencing studies have uncovered an array of distinct genomic drivers underlying various ovarian cancer subtypes. If researchers can capitalize on these discoveries, it may offer a path to more individualized and effective treatment options.
By: Robert Wechsler-Reya, PhD
To discover targeted therapies for the more common and severe types of medulloblastoma, a laboratory at Sanford Burnham Prebys Medical Discovery Institute has led efforts to develop genetically engineered mouse models and patient-derived xenografts for studying the molecular basis of the disease.
By: Maurie Markman, MD
Although chemotherapy has changed dramatically since it was introduced, platinum-containing combinations remain standard in ovarian cancer. Often, the established regimen can be modified for patients who quite justifiably may fear the toxicities of platinum agents.